What is HC Wainwright’s Estimate for VNDA Q1 Earnings?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Vanda Pharmaceuticals in a research report issued on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju anticipates that the biopharmaceutical company will post earnings per share of ($0.08) for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.10 EPS and Q4 2026 earnings at $0.14 EPS.

Separately, StockNews.com initiated coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a “hold” rating on the stock.

Vanda Pharmaceuticals Stock Down 1.3 %

VNDA stock opened at $4.49 on Wednesday. Vanda Pharmaceuticals has a twelve month low of $3.71 and a twelve month high of $6.75. The firm has a market cap of $261.86 million, a PE ratio of -14.03 and a beta of 0.74. The business has a 50 day moving average of $4.60 and a 200 day moving average of $4.82.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The company had revenue of $53.19 million during the quarter, compared to analyst estimates of $51.00 million.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Large investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its position in Vanda Pharmaceuticals by 10.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company’s stock worth $11,920,000 after acquiring an additional 227,428 shares in the last quarter. Geode Capital Management LLC grew its position in Vanda Pharmaceuticals by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 1,450,310 shares of the biopharmaceutical company’s stock worth $6,949,000 after acquiring an additional 24,483 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in Vanda Pharmaceuticals by 4.9% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company’s stock worth $3,925,000 after acquiring an additional 38,449 shares in the last quarter. Federated Hermes Inc. grew its position in Vanda Pharmaceuticals by 1.4% in the fourth quarter. Federated Hermes Inc. now owns 726,619 shares of the biopharmaceutical company’s stock worth $3,481,000 after acquiring an additional 9,840 shares in the last quarter. Finally, Millennium Management LLC grew its position in Vanda Pharmaceuticals by 67.4% in the fourth quarter. Millennium Management LLC now owns 668,693 shares of the biopharmaceutical company’s stock worth $3,203,000 after acquiring an additional 269,183 shares in the last quarter. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.